Objective. Magnetic resonance techniques have recently been investigated as tools with which to monitor inflammatory joint disease. Our aim was to use a contrast-enhanced T1-weighted protocol to monitor the short-term changes in knee synovial lining volume in a double-blind, randomized, controlled trial of intra-articular samarium-153 particulate hydroxyapatite (Sm-153 PHYP).
An increase in synovial lining thickness or synovial to estimate SLV in studies evaluating therapy for chronic lining volume (SLV ) is a consistent feature of chronically synovitis [3] [4] [5] [6] . inflamed joints [1] . Magnetic resonance (MR) techSamarium-153 particulate hydroxyapatite (Sm-153 niques have been developed, using contrast-enhanced PHYP) is a particulate radiopharmaceutical developed T1-weighted sequences, that facilitate quantitative measfor medical synovectomy [8, 9] . It is administered simply urement of SLV [2] [3] [4] . These techniques have been used by joint injection and is highly retained in injected joints [9] . Its use in out-patients with chronic knee synovitis has been associated with short-term symptom relief
Submitted 30 April 1998; revised version accepted 17 September without unwanted effects [10] . However, comparisons It is worth noting that one of the major problems in comparing the large number of (mainly non-MR study. Formal clinical review was not undertaken as part of this study. Long-term symptomatic response randomized) radiation synovectomy efficacy studies has been in interpreting the variety of outcome measures of the 'parent' patient cohort will be reported separately (manuscript in preparation). used [11, 12] . Frequently, the measures have been clinically based examination indices: largely qualitative and MR methodology derived subjectively. The development of objective techniques, such as quantitative MR, which are able to All patients were examined on a 1 T scanner (Siemens Magnetom 42SP) in a circularly polarized transmit and quantify outcome, may be helpful for evaluating existing and new treatments for synovitis.
receive knee coil the week before and 3 months after treatment. The post-treatment MR study was timed to Our aim was to measure changes in SLV in the short term by quantitative MR [7] in a sample of patients balance the chance of observing an optimal, though, as far as was practicable, clinically relevant (prolonged) with chronic knee synovitis recruited to a double-blind, randomized, controlled trial comparing combined intraeffect of both intra-articular glucocorticoid and the particulate radiopharmaceutical on the synovitis. This articular Sm-153 PHYP and steroid injection with intraarticular steroid alone.
was Scanning details and image analysis methods are synovitis, who were recruited to a large double-blind, described in detail elsewhere [7] . In brief, the knee was randomized, intra-articular glucocorticoid-controlled stabilized with foam padding and the foot stabilized study of the long-term effects of Sm-153 PHYP, were with sandbags. A long i.v. line with a 21-gauge butterfly then asked to join the MR study. Inclusion criteria for needle was inserted in the forearm before the procedure. the whole study were: age 18 yr or older, chronic knee
The evaluation of SLV was made from threesynovitis for at least 2 yr, and clinical indication for dimensional T1-weighted magnetization prepared rapid intra-articular therapy judged by knee pain and stiffness acquisition gradient echo (MP RAGE) sequences [14] being the factor limiting mobility. Exclusion criteria ( TR 10 ms; TE 4 ms; TI 500 ms; FA 40°; FOV 210 mm; were: Steinbrocker radiological grade III/IV [13] for Ma 256 × 256; slice thickness 2 mm; Nex 1; Tacq 9 min) rheumatoid arthritis (RA) patients or <2 mm tibiomade before and after i.v. injection of 0.1 mmol/kg femoral joint space scored on a weight-bearing anteropodimeglumine gadopentetate (Gd-DTPA) [Magnevist@, sterior knee radiograph (non-RA patients), any form of
Schering Healthcare]. Scan datasets were transferred to intra-articular therapy within the previous 3 months, a Sun SPARC 2 WorkStation and analysed by an and a change in type or dose of slow-acting antiinvestigator blind to treatment randomization (GC ). rheumatic drug (SAARD) within the previous 3 months.
Pre-and post-enhancement images were subtracted The study was approved by the UCL Hospitals Trust using in-house software and, using XDISPIM ( UCL, Ethical Committee and all patients signed a written London), enhancing, non-vascular structures were informed consent.
manually segmented in each sagittal slice. Sagittal images Treatment procedure were preferred to axial images for analysis because, in our experience, the synovial lining image was easier to Randomization codes were held by the radiopharmacist. Patients were given either 40 mg triamcinolone hexacetinterpret, could be more simply segmented, and could in many slices be segmented in a single region of interest. onide ( TH ) alone or in combination with 555 MBq (13.2 mCi) Sm-153 PHYP as a single intra-articular It was reasoned that total image analysis time and errors inherent in manual segmentation of an image would, injection, by an investigator blinded to the randomization code. The injection procedure has been described therefore, be minimized. Total pixel area above the optimum preset threshold of the signal intensity on the in detail [9] . In brief, joints were aspirated, then injected using a 21-gauge needle attached to a three-way tap post-minus pre-enhancement subtraction images [7] was calculated and total voxel volume derived as a attached to two syringes, one containing the treatment substance and the second, a saline flush. The system measure of the volume of enhancing synovial tissue. was fully flushed to ensure full delivery of the drug(s).
Statistical analysis To maintain blinding, the syringe containing the drug and the three-way tap were obscured by tape.
Baseline SLVs were distributed approximately continuously. The significance of the difference in mean preSubsequently, patients were kept non-weight bearing with knees immobilized for 4 h using a semi-rigid splint.
treatment SLV in the two treatment groups and the difference between mean per cent change in SLV in the Injected radioactivity was calculated by subtraction of activity remaining in the injection apparatus after injectwo groups after treatment was compared by two-tailed Student's t-test. The paired t-test was used to test the tion from prepared activity. Patients were reviewed clinically for unwanted effects related to the treatment significance of the mean change in SLV within each group after treatment. prior to discharge and when they returned for the second
There was no significant difference in mean baseline to examine the relationship between pre-treatment SLVs and the per cent change in SLV after treatment, both SLV in the two treatment groups ( Joint aspiration and injection were completed group. For correlation, significance was tested (a = 0.05) using one-way analysis of variance (ANOVA).
uneventfully in each case. There were no local sideeffects observed immediately after the procedure or reported after the treatment. Within the study period,
Results
no patient discontinued or changed the dose of their SAARD. Twenty-four patients were recruited to the MR study. Four patients subsequently withdrew: two after the There was a non-significant reduction in mean SLV in the Sm-153 PHYP/TH-treated group (139 to 110 ml, initial MR and two between treatment and the second MR. Poor contrast enhancement and movement artefact P = 0.07), but a significant reduction in mean SLV in the TH-treated group (127 to 58 ml, P < 0.001) by 3 resulted in image degradation in a further two patient studies which precluded paired image analysis. months after treatment. The size of the reduction was significantly greater in patients treated with TH alone Therefore, pre-and post-treatment MR data were available for 18/24 (75%) patients. Clinical details of these (−61% vs −23%, P < 0.05) ( Table 2 ). An example of paired pre-and post-treatment subtraction MR images 18 patients are shown in Table 1 . Diagnoses were: RA (n = 7) diagnosed according to ARA criteria [15] ; juvenis shown in Fig. 1 The maximum reduction of SLV achieved was similar in both groups (~− 95%), but in ile chronic arthritis (n = 1); seronegative spondylarthritis-consisting of patients with a characteristic the combined-treatment group there were 5/9 patients in whom the SLV changed <15% after treatment. inflammatory arthropathy clearly associated with psoriasis (n = 3) and patients with a proven characteristic
There was a weak non-significant correlation between baseline SLV and per cent reduction in SLV overall infection prior to the onset of chronic oligoarticular arthritis (n = 1; in this case, sexually acquired reactive (R p = −0.4, P = 0.14, n = 18) in the Sm-153 PHYP/TH-treated group (R p = −0.2, P = 0.60, arthritis); and finally patients who were rheumatoid factor seronegative with oligo-or monoarticular n = 9) and in the TH-treated group (R p = −0.5, P = 0.14, n = 9). There was no clear relationship inflammatory arthritis in whom the diagnosis had not between the injected activity of Sm-153 PHYP and change in SLV (R s = −0.3, P = 0.50, n = 9). (n = 9) (n = 9) (yr) 6 (3-24) 8 (2-25) Median (range) number of Mean (± ..) baseline 139 (± 56) 127 (± 48) SLV (ml ) P = 0.07a months since last knee joint 5 (3-24) 4 (3-18) steroid injection Mean (± ..) post-treatment 110 (± 68) 58 (± 57) SLV (ml ) Patients taking non-steroidal anti-inflammatory drugs 7 4 Mean (± ..) reduction in −23 (±34) −61 (±33) SLV (%) P < 0.05a Patients taking SAARDs 6 4 Median (range) change in −13% −56% SLV (+6% to −94%) (−12% to −97%) aUndifferentiated seronegative oligoarthritis (2) . bUndifferentiated seronegative oligoarthritis (2); monoarthritis associated with polyarteritis nodosa; and monoarthritis associated SLV, synovial lining volume. aSignificance calculated using two-tailed Student's t-test. with ulcerative colitis. timal synovial tissue mass [16 ] , although other aspects be consistent with the arthroscopic finding that Y-90 colloid may initially increase synovial thickening of joint tissue such as subintimal fibrosis [17] may influence measurements. Measurements of tissue
[21] before resulting in an improvement. It should also be noted that in the combined-treatment group more volume, however, may be approximate as results may be affected by the timing of the i.v. contrast injection patients were taking both non-steroidal antiinflammatory drugs (NSAIDs) and SAARDs, sugand post-contrast-enhanced T1-weighted sequence, by partial volume effects and by movement artefact if the gesting a greater extent and/or severity of polyarticular synovitis ( Table 1) , and that baseline mean SLV was joint is not kept still between sequences [2, 6, 7] . Nevertheless, previous analyses have shown that, from greater than in the combined-treatment group ( Table 2) , both factors recognized to be associated with poorer errors associated with the technique, SLV changes in excess of 15% are likely to be significant [7] and thus outcome from radiation synovectomy [12] . These data were obtained despite randomization and may have the mean reduction in SLV from both combined Sm-153 PHYP/TH treatment and TH alone is significant 3 contributed to bias. There was no significant correlation between premonths after treatment.
The size of the reduction in SLV and the number of treatment SLV and per cent reduction in SLV overall or in either group. There are too few data in each group patients who achieved a >15% reduction in SLV was greater in the TH-treated compared to the combinedto allow a rigorous analysis of this relationship; however, subgroup analysis suggested that there was a greater treatment group. The efficacy in both groups could be explained on account of the effects of intra-articular strength of this relationship in the TH-only-treated group than in the combined-treatment group. Larger steroid alone. It is possible that Sm-153 PHYP may have initially aggravated the synovitis either through a studies would be needed to explore this relationship further. mild pro-inflammatory effect of the particulate hydroxyapatite [18] or perhaps as a result of the initial 'theraThere was no clear relationship between injected Sm-153 PHYP activity and change in SLV. In view of peutic' effect of the radiation causing tissue necrosis, fibrin deposition and synovial lining thickening, similar the absence of any detailed Sm-153 dosimetry studies, we had aimed to inject~555 MBq (15 mCi) Sm-153. to that observed following joint injection of Y-90 colloid [19] [20] [21] . Thus, these effects may have led to a more This activity was estimated to give a dose to synovium roughly equivalent to the dose given by 185 MBq variable but overall lesser effect of combined Sm-153 PHYP and TH injection in reducing SLV in the short (5 mCi) of yttrium-90 ( Y-90) [9], a dose associated with a clinical response in the long term [22] . Mean term. It is interesting to note that co-injection of Y-90 colloid and glucocorticoid leads to a wide variation in injected Sm-153 activity was 490 MBq (13.2 mCi). The minimum injected was 300 MBq (8.1 mCi) and the MR-quantified SLV with no significant change in median SLV after 12 weeks [6 ] . These results might also maximum 725 MBq (19.6 mCi). The variation in dose
